Loading...

Bio-Gene Technology Limited

BGT.AXASX
Healthcare
Biotechnology
A$0.02
A$0.00(0.00%)

Bio-Gene Technology Limited (BGT.AX) Stock Competitors & Peer Comparison

See (BGT.AX) competitors and their performances in Stock Market.

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
BGT.AXA$0.02+0.00%5.8M-1.90-A$0.01N/A
CSL.AXA$264.05-2.53%127.9B31.55A$8.37+1.61%
TLX.AXA$20.15-4.28%6.8B143.93A$0.14N/A
MSB.AXA$2.35-1.26%3B-12.37-A$0.19N/A
NEU.AXA$16.93-2.08%2.1B15.53A$1.09N/A
CU6.AXA$4.46+2.06%1.4B-27.87-A$0.16N/A
OPT.AXA$0.60+0.00%738.8M-1.40-A$0.43N/A
PYC.AXA$1.21-2.42%705.7M-11.00-A$0.11N/A
CUV.AXA$12.43-4.16%623M16.14A$0.77+0.40%
IMM.AXA$0.26-3.70%381.6M-8.67-A$0.03N/A
Showing 1 to 10 of 57 results
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

BGT.AX vs CSL.AX Comparison August 2025

BGT.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGT.AX stands at 5.8M. In comparison, CSL.AX has a market cap of 127.9B. Regarding current trading prices, BGT.AX is priced at A$0.02, while CSL.AX trades at A$264.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGT.AX currently has a P/E ratio of -1.90, whereas CSL.AX's P/E ratio is 31.55. In terms of profitability, BGT.AX's ROE is -1.15%, compared to CSL.AX's ROE of +0.15%. Regarding short-term risk, BGT.AX is more volatile compared to CSL.AX. This indicates potentially higher risk in terms of short-term price fluctuations for BGT.AX.Check CSL.AX's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions

;